Year to date highlights include: OPERATIONAL HIGHLIGHTS: – Manufacturing: alliances in vector manufacturing, research, development and IP Novartis development and manufacturing collaboration announced in May: – Oxford BioMedica to manufacture a lentiviral vector encoding CTL019 – Expected to generate between A 2.5 million to A 4 million of income … (more)
